5J2P image
Deposition Date 2016-03-29
Release Date 2016-08-03
Last Version Date 2025-07-02
Entry Detail
PDB ID:
5J2P
Keywords:
Title:
HIV-1 reverse transcriptase in complex with DNA that has incorporated EFdA-MP at the P-(post-translocation) site and a second EFdA-MP at the N-(pre-translocation) site
Biological Source:
Method Details:
Experimental Method:
Resolution:
2.53 Å
R-Value Free:
0.24
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:reverse transcriptase, p66 domain
Gene (Uniprot):gag-pol
Mutations:Q258C, C280S
Chain IDs:A
Chain Length:560
Number of Molecules:1
Biological Source:Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)
Polymer Type:polypeptide(L)
Molecule:reverse transcriptase, p51 domain
Gene (Uniprot):gag-pol
Mutations:C280S
Chain IDs:B
Chain Length:440
Number of Molecules:1
Biological Source:Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)
Polymer Type:polydeoxyribonucleotide
Molecule:DNA (5'-D(*AP*CP*AP*GP*TP*CP*CP*CP*TP*GP*TP*TP*CP*GP*GP*(MRG)P*CP*GP*CP*CP*(6FM)P*(6FM))-3')
Chain IDs:C (auth: P)
Chain Length:22
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
Polymer Type:polydeoxyribonucleotide
Molecule:DNA (27-MER)
Chain IDs:D (auth: T)
Chain Length:27
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
Primary Citation
Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).
Proc.Natl.Acad.Sci.USA 113 9274 9279 (2016)
PMID: 27489345 DOI: 10.1073/pnas.1605223113

Abstact

4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is the most potent nucleoside analog inhibitor of HIV reverse transcriptase (RT). It retains a 3'-OH yet acts as a chain-terminating agent by diminishing translocation from the pretranslocation nucleotide-binding site (N site) to the posttranslocation primer-binding site (P site). Also, facile misincorporation of EFdA-monophosphate (MP) results in difficult-to-extend mismatched primers. To understand the high potency and unusual inhibition mechanism of EFdA, we solved RT crystal structures (resolutions from 2.4 to 2.9 Å) that include inhibition intermediates (i) before inhibitor incorporation (catalytic complex, RT/DNA/EFdA-triphosphate), (ii) after incorporation of EFdA-MP followed by dT-MP (RT/DNAEFdA-MP(P)• dT-MP(N)), or (iii) after incorporation of two EFdA-MPs (RT/DNAEFdA-MP(P)• EFdA-MP(N)); (iv) the latter was also solved with EFdA-MP mismatched at the N site (RT/DNAEFdA-MP(P)• EFdA-MP(*N)). We report that the inhibition mechanism and potency of EFdA stem from interactions of its 4'-ethynyl at a previously unexploited conserved hydrophobic pocket in the polymerase active site. The high resolution of the catalytic complex structure revealed a network of ordered water molecules at the polymerase active site that stabilize enzyme interactions with nucleotide and DNA substrates. Finally, decreased translocation results from favorable interactions of primer-terminating EFdA-MP at the pretranslocation site and unfavorable posttranslocation interactions that lead to observed localized primer distortions.

Legend

Protein

Chemical

Disease

Primary Citation of related structures